Pliant Therapeutics (NASDAQ:PLRX) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRXFree Report) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $36.00 price objective on the stock.

PLRX has been the topic of several other reports. Needham & Company LLC reissued a buy rating and set a $38.00 target price on shares of Pliant Therapeutics in a research report on Tuesday, May 7th. Royal Bank of Canada decreased their target price on Pliant Therapeutics from $54.00 to $45.00 and set an outperform rating for the company in a research report on Tuesday, May 7th. Oppenheimer upped their price objective on shares of Pliant Therapeutics from $47.00 to $48.00 and gave the stock an outperform rating in a report on Tuesday, May 7th. Finally, Citigroup dropped their target price on shares of Pliant Therapeutics from $45.00 to $44.00 and set a buy rating on the stock in a report on Tuesday, May 7th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, Pliant Therapeutics presently has an average rating of Buy and a consensus target price of $45.67.

Read Our Latest Stock Report on PLRX

Pliant Therapeutics Price Performance

Shares of PLRX stock opened at $15.27 on Wednesday. The stock’s 50-day moving average is $13.98 and its two-hundred day moving average is $15.42. Pliant Therapeutics has a fifty-two week low of $11.21 and a fifty-two week high of $24.74. The company has a quick ratio of 16.12, a current ratio of 16.12 and a debt-to-equity ratio of 0.07.

Pliant Therapeutics (NASDAQ:PLRXGet Free Report) last posted its earnings results on Monday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.02). As a group, analysts anticipate that Pliant Therapeutics will post -3.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its stake in Pliant Therapeutics by 97.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,529 shares of the company’s stock worth $27,000 after purchasing an additional 754 shares during the period. Arizona State Retirement System boosted its stake in Pliant Therapeutics by 6.4% in the 4th quarter. Arizona State Retirement System now owns 12,545 shares of the company’s stock valued at $227,000 after buying an additional 754 shares in the last quarter. ProShare Advisors LLC grew its position in Pliant Therapeutics by 9.1% in the first quarter. ProShare Advisors LLC now owns 14,489 shares of the company’s stock valued at $216,000 after acquiring an additional 1,203 shares during the period. New York State Common Retirement Fund raised its stake in Pliant Therapeutics by 3.5% during the third quarter. New York State Common Retirement Fund now owns 50,575 shares of the company’s stock worth $877,000 after acquiring an additional 1,725 shares in the last quarter. Finally, Quest Partners LLC bought a new position in shares of Pliant Therapeutics during the fourth quarter valued at $37,000. 97.30% of the stock is owned by institutional investors.

Pliant Therapeutics Company Profile

(Get Free Report)

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.

Featured Articles

Analyst Recommendations for Pliant Therapeutics (NASDAQ:PLRX)

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.